GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q BioMed Inc (OTCPK:QBIO) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Q BioMed (Q BioMed) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of May. 28, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Q BioMed EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Q BioMed's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.


Competitive Comparison of Q BioMed's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, Q BioMed's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Q BioMed's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q BioMed's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Q BioMed's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.



Q BioMed  (OTCPK:QBIO) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.


Q BioMed EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Q BioMed's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.


Q BioMed (Q BioMed) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q BioMed Inc (OTCPK:QBIO) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)
Traded in Other Exchanges
N/A
Address
C/o Ortoli Rosenstadt LLP, 366 Madison Avenue, 3rd Floor, New York, NY, USA, 10017
Q BioMed Inc is a biomedical acceleration and development company. It has a focus on licensing, acquiring, and providing strategic resources to life sciences and healthcare companies. The company intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare-related products, companies, and sectors. Generic Strontium Chloride Sr-89 Injection USP (Strontium-89) is a radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. It also has three development-stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder, Uttroside-B for liver cancer, and MAN 01 for glaucoma.
Executives
William S Rosenstadt director, 10 percent owner, officer: Chief Legal Officer ORTOLI ROSENSTADT LLP, 501 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Denis Corin director, 10 percent owner, officer: Chief Executive Officer 10 MARKET STREET, SUITE 427, GRAND CAYMAN E9 KY1-9006
Rick Panicucci director 501 MADISON STREET, 14TH FLOOR, NEW YORK NY 10022
Alan P Lindsay 10 percent owner 580 HORNBY STREET, FIFTH FLOOR, VANCOUVER BC CANADA V6C 2E7 A1